5:29 PM
 | 
Oct 18, 2013
 |  BC Extra  |  Company News

FDA panel backs Impavido for leishmaniasis

FDA's Anti-Infective Drugs Advisory Committee was unfazed by FDA reviewers' concerns over trial inconsistencies and resistance to Impavido miltefosine from Paladin Labs Inc. (TSX:PLB). The panel voted 15-1, 14-2 and 13-3 that the company had adequately demonstrated the safety and efficacy of Impavido to treat visceral,...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >